Japan Tobacco and Torii Pharmaceutical Conclude Marketing Agreement

Source from:  Datamonitor  09/10/2012

Japan Tobacco Inc and Torii Pharmaceutical Co, Ltd have announced the conclusion of an agreement to market an anti-HIV single-tablet regimen containing JT's original compound JTK-303 in Japan, subsequent to obtaining marketing approval from the country's authorities. JT plans to submit a New Drug Application (NDA) in Japan within this fiscal year ending March 31, 2013. Following Japanese NDA approval, this anti-HIV single-tablet regimen, marketed in the US as Stribild, will be sold exclusively by Torii in Japan. The single-tablet regimen contains JTK-303, an integrase inhibitor, and in addition, Emtriva and Viread which are nucleoside analogue reverse transcriptase inhibitors, as well as cobicistat, a pharmacoenhancing or 'boosting' agent that increases blood levels of JTK-303. The drug allows for only once-daily and single-tablet dosing, expected to enhance the convenience and long-term compliance of patients. Currently in the JT Group, Torii has been marketing anti-HIV drugs in Japan including Truvada Combination Tab., Emtriva Capsules 200mg, Viread Tab. 300mg and Viracept Tab. 250mg. Marketing of the drug in Japan, following approval, would constitute another contribution by JT Group to the treatment of HIV. Enditem